Michael S. Oh

1.3k total citations
36 papers, 707 citations indexed

About

Michael S. Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael S. Oh has authored 36 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Michael S. Oh's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Genomics and Diagnostics (10 papers). Michael S. Oh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Genomics and Diagnostics (10 papers). Michael S. Oh collaborates with scholars based in United States, South Korea and Japan. Michael S. Oh's co-authors include Young Kwang Chae, Francis J. Giles, Jonathan F. Anker, Preeti Bais, Curtis Schauder, Karin M. Reinisch, Jeremy M. Baskin, Sandeep Namburi, Pietro De Camilli and Victoria Villaflor and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Nature Cell Biology.

In The Last Decade

Michael S. Oh

32 papers receiving 699 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael S. Oh United States 15 306 257 220 196 120 36 707
Nikolas G. Balanis United States 12 424 1.4× 425 1.7× 232 1.1× 215 1.1× 100 0.8× 15 822
Kruttika Bhat United States 13 289 0.9× 393 1.5× 96 0.4× 239 1.2× 114 0.9× 21 806
Mario Caccese Italy 17 242 0.8× 253 1.0× 224 1.0× 211 1.1× 74 0.6× 70 883
Ashwin Somasundaram United States 12 397 1.3× 304 1.2× 146 0.7× 121 0.6× 291 2.4× 33 804
Fahao Zhang United States 16 310 1.0× 491 1.9× 196 0.9× 124 0.6× 155 1.3× 25 844
Yanpeng Ci China 8 535 1.7× 387 1.5× 260 1.2× 113 0.6× 230 1.9× 8 849
Khoi Chu United States 15 468 1.5× 432 1.7× 218 1.0× 188 1.0× 70 0.6× 22 869
Gvantsa Kharaishvili Czechia 18 347 1.1× 404 1.6× 153 0.7× 221 1.1× 62 0.5× 26 776
Leilei Tao China 11 358 1.2× 407 1.6× 91 0.4× 306 1.6× 158 1.3× 18 765
Evelyn A. Kono United States 7 243 0.8× 313 1.2× 204 0.9× 99 0.5× 119 1.0× 11 635

Countries citing papers authored by Michael S. Oh

Since Specialization
Citations

This map shows the geographic impact of Michael S. Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Oh more than expected).

Fields of papers citing papers by Michael S. Oh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Oh. The network helps show where Michael S. Oh may publish in the future.

Co-authorship network of co-authors of Michael S. Oh

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Oh. A scholar is included among the top collaborators of Michael S. Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Oh. Michael S. Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oh, Michael S., Edward B. Garon, Aaron Lisberg, et al.. (2025). Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients. Clinical Lung Cancer. 26(5). 434–439.e3.
2.
3.
4.
Oh, Michael S., Camelia Dumitras, Ramin Salehi‐Rad, et al.. (2024). Characteristics of a CCL21 Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 24(2). 286–298. 6 indexed citations
5.
Lim, Raymond J., Ramin Salehi‐Rad, Linh M. Tran, et al.. (2024). CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Reports Medicine. 5(4). 101479–101479. 46 indexed citations
6.
Oh, Michael S., et al.. (2023). Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment. Cells. 12(19). 2404–2404. 8 indexed citations
7.
8.
Park, Jonghanne, Youjin Oh, Elena Vagia, et al.. (2021). Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis. Translational Lung Cancer Research. 10(4). 1700–1710. 6 indexed citations
9.
Oh, Michael S., Jonathan F. Anker, & Young Kwang Chae. (2021). High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC. Cancer Treatment and Research Communications. 27. 100317–100317. 11 indexed citations
10.
Davis, Andrew A., Wade T. Iams, David Chan, et al.. (2020). Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. Molecular Cancer Therapeutics. 19(7). 1486–1496. 17 indexed citations
11.
Cho, Geum Joon, et al.. (2020). <p>Peripartum Blood Transfusions are Associated with Increased Risk of Cancer: A National Retrospective Cohort Study</p>. Clinical Epidemiology. Volume 12. 659–666. 1 indexed citations
12.
Oh, Michael S., Derek A. Wainwright, Nisha Mohindra, et al.. (2020). The Impact of Beta Blockers on Survival Outcomes in Patients With Non–small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clinical Lung Cancer. 22(1). e57–e62. 57 indexed citations
13.
Davis, Andrew A., Jonghanne Park, Wade T. Iams, et al.. (2020). Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer. Cancer Research. 80(16_Supplement). 5527–5527. 1 indexed citations
14.
Rich, Thereasa A., Karen L. Reckamp, Young Kwang Chae, et al.. (2019). Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research. 25(19). 5832–5842. 68 indexed citations
15.
Chae, Young Kwang, Jonathan F. Anker, Michael S. Oh, et al.. (2019). Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. Scientific Reports. 9(1). 3235–3235. 55 indexed citations
16.
Burns, Michael C., et al.. (2019). EP1.04-12 Response to Combination of Metformin and Nivolumab in a NSCLC Patient Whose Disease Previously Progressed on Nivolumab. Journal of Thoracic Oncology. 14(10). S976–S976. 3 indexed citations
17.
Davis, Andrew A., Wade T. Iams, David Chan, et al.. (2019). P1.01-49 Serial Changes in Whole-Genome Cell-Free DNA (cfDNA) to Identify Disease Progression Prior to Imaging in Advanced NSCLC. Journal of Thoracic Oncology. 14(10). S377–S377. 1 indexed citations
18.
Lees, Joshua A., Yixiao Zhang, Michael S. Oh, et al.. (2017). Architecture of the human PI4KIIIα lipid kinase complex. Proceedings of the National Academy of Sciences. 114(52). 13720–13725. 47 indexed citations
19.
Baskin, Jeremy M., Xudong Wu, Romain Christiano, et al.. (2015). The leukodystrophy protein FAM126A (hyccin) regulates PtdIns(4)P synthesis at the plasma membrane. Nature Cell Biology. 18(1). 132–138. 85 indexed citations
20.
Pandey, Ambarish, Ashish Kulkarni, Bhaskar Roy, et al.. (2013). Sequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor Efficacy. Cancer Research. 74(3). 675–685. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikolas G. Balanis Breakdown of academic impact, for papers by Kruttika Bhat Breakdown of academic impact, for papers by Mario Caccese Breakdown of academic impact, for papers by Ashwin Somasundaram Breakdown of academic impact, for papers by Fahao Zhang Breakdown of academic impact, for papers by Yanpeng Ci Breakdown of academic impact, for papers by Khoi Chu Breakdown of academic impact, for papers by Gvantsa Kharaishvili Breakdown of academic impact, for papers by Leilei Tao Breakdown of academic impact, for papers by Evelyn A. Kono
Rankless by CCL
2026